arrow
N

Nandita R. Nadig

Northwestern University Feinberg School of Medicine
H指数:11
被引数:479

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Daily Clinical Parameters and Outcomes Adjudication Dataset for Critically Ill Patients with Suspected Pneumonia

疑似肺炎重症患者的日临床参数及结局判定数据集

2026-10-150
OA
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

2025年美国传染病学会关于COVID-19治疗和管理的临床实践指南更新:成人轻度至中度COVID-19的抗病毒治疗

2026-04-010
PRE
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:巴瑞替尼与托珠单抗

2026-04-010
PRE
258: EVALUATING PHYSICIAN VARIABILITY IN USE OF TIME-LIMITED TRIALS IN MECHANICALLY VENTILATED PATIENTS

258: 评估机械通气患者中使用限时试验的医师变异情况

2026-03-030
PRE
TIME-LIMITED TRIALS: AN ETHNOGRAPHIC STUDY COMPARING WORK-AS-ENVISIONED TO WORK-AS-PERFORMED

限时试验:一项比较预期工作与实际工作的民族志研究

2026-03-010
PRE
Optimising time-limited trials in acute respiratory failure: a multicentre focused ethnography protocol

优化急性呼吸衰竭的时间限制性试验:一项多中心聚焦民族志研究方案

2025-12-120
OA
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

2025年美国传染病学会关于COVID-19治疗和管理临床实践指南更新:Pemivibart用于暴露前预防,Vilobelimab用于危重疾病,Abatacept或Infliximab用于严重或危重疾病

2025-10-010
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept

2025年美国传染病学会关于COVID-19治疗和管理的临床实践指南更新:Abatacept

2025-09-010
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:Infliximab

2025-08-011
OAAI
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

2025年美国传染病学会关于COVID-19治疗与管理的临床实践指南更新:Vilobelimab

2025-07-011
OAAI
Antibiotic de-escalation patterns and outcomes in critically ill patients with suspected pneumonia as informed by bronchoalveolar lavage results

重症患者中,根据支气管肺泡灌洗结果指导的抗生素降级模式与结果(针对疑似肺炎病例)

2025-05-030
OA
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

美国传染病学会关于新型冠状病毒肺炎管理的2024临床实践指南更新: Anti-SARS-CoV-2中和抗体Pemivibart用于暴露前预防

2024-10-291
PRE
Evolution of Investigating Informed Assent Discussions about CPR in Seriously Ill Patients
2022-06-011
OAAI
Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
2021-12-0414
OAAI